FilingSEC EDGAR8-K
Lyell Immunopharma Completes LYL273 Manufacturing Technology Transfer and Updates Clinical Timeline
· SEC accepted
StagePhase 1/2
Filing content
Lyell Immunopharma has completed the technology transfer for LYL273 following FDA review and now expects to share additional clinical data and hold an End-of-Phase 1 meeting with the FDA in 2027.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…